Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TAK-330 versus 4F-PCC for urgent reversal of factor Xa inhibitor anticoagulation before high-bleeding-risk surgery
NL-OMON60876Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Prothromplex Total in anticoagulation therapy, sponsored by Takeda. Started Nov 2022; status: completed.
02
Drugs
Prothromplex Total
03
Conditions
anticoagulation therapy
Beyond the preview
Go deeper on NL-OMON60876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60876.